Edgewise Therapeutics Newsroom

Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group

Dow JonesNov 22 22:53

Evercore Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45

Futu NewsNov 22 21:31

Edgewise Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesNov 8 23:36

Edgewise Therapeutics Analyst Ratings

BenzingaNov 8 23:26

RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42

Futu NewsNov 8 20:31

Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51

Futu NewsOct 31 02:32

Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating

Futu NewsOct 22 19:31

Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51

Futu NewsOct 11 19:36

Edgewise Therapeutics Analyst Ratings

BenzingaOct 11 19:29

Piper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)

TipRanksOct 11 18:42

Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)

TipRanksOct 8 16:02

Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33

Futu NewsSep 26 10:31

Edgewise Therapeutics (EWTX) Gets a Buy From Truist Financial

TipRanksSep 26 10:28

Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33

Futu NewsSep 21 20:33

Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44

Futu NewsSep 20 22:32

Edgewise Therapeutics Analyst Ratings

BenzingaSep 20 21:14

Leerink Partners Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $42

Futu NewsSep 20 02:32

Buy Rating Affirmed on Edgewise Therapeutics' EDG-7500 for HCM Treatment Due to Promising Efficacy and Safety Profile

TipRanksSep 20 02:27

Edgewise Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesSep 20 02:11

Wedbush Adjusts Edgewise Therapeutics Price Target to $44 From $31, Maintains Outperform Rating

MT NewswiresSep 20 00:32